SCHEMBL3007690

SCHEMBL3007690

CCc1ccc(Cc2csc(N3CCN(S(=O)(=O)c4cc(Cl)ccc4OC)CC3)n2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.52
CYP2C19 P33261 2/20 0.52
LMNA P02545 6/20 0.51
MAPT P10636 5/20 0.51
ALDH1A1 P00352 5/20 0.51
TSHR P16473 2/20 0.51
KDM4E B2RXH2 1/20 0.51
POLB P06746 1/20 0.51
HPGD P15428 1/20 0.51
RAB9A P51151 1/20 0.51
SMN1; SMN2 Q16637 2/20 0.47
HTT P42858 3/20 0.46
TP53 P04637 2/20 0.46
ALOX12 P18054 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
CYP2C9 P11712 1/20 0.44
GAA P10253 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
USP2 O75604 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3015393 0.95 ALDH1A1 (0.54) CYP3A4CYP2C19LMNAMAPTALDH1A1
SCHEMBL3017691 0.93 CYP3A4 (0.52) CYP3A4CYP2C19LMNAMAPTALDH1A1
SCHEMBL3013689 0.93 LMNA (0.51) CYP3A4CYP2C19LMNAMAPTALDH1A1
SCHEMBL3014738 0.93 KMT2A (0.53) CYP3A4CYP2C19LMNAMAPTALDH1A1
SCHEMBL3007463 0.92 ALDH1A1 (0.52) CYP3A4CYP2C19LMNAMAPTALDH1A1
SCHEMBL3007189 0.92 ALDH1A1 (0.52) CYP3A4CYP2C19LMNAMAPTALDH1A1
SCHEMBL3017175 0.91 LMNA (0.52) CYP3A4CYP2C19LMNAMAPTALDH1A1
SCHEMBL3008917 0.91 MAPT (0.51) CYP3A4CYP2C19LMNAMAPTALDH1A1
SCHEMBL3005319 0.91 ALDH1A1 (0.53) CYP3A4CYP2C19LMNAMAPTALDH1A1
SCHEMBL3010974 0.90 ALDH1A1 (0.56) LMNAMAPTALDH1A1TSHRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed
EP-2188272-A2 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV Remynd (BE) 2010-05-26 EP disclosed
WO-2009019295-A2 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV REMYND (BE) 2009-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA CYP3A4 4794/4885CYP2C19 4845/4885LMNA 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.